Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU study of gantenerumab and solanezumab in dominantly inherited Alzheimer's disease
2013-000307-17Phase 2Unknown
- Sponsor
- Washington University in St. Louis
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Gantenerumab, Solanezumab and Pooled placebo (3 arms). Primary endpoint: Relative rate of cognitive decline on DIAN-TU Cognitive Composite. Status: unknown.
02
Drugs
gantenerumabsolanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2013-000307-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000307-17.